Even in a tough IPO market, women’s health companies continue to exit with tremendous valuations. At Amboy Street, we started tracking these exits by kicking off our annual Top 10 Deals blog series in 2021. With our 2024 Top 10 Deals series now complete, we’re diving deeper—highlighting the most active acquirers shaping the future of women’s and sexual health.
Over the past four years, three key acquirer profiles have emerged:
Pharmaceutical / MedTech Giants:
Major players in Pharma and MedTech are actively acquiring in women’s health, expanding their portfolios through strategic deals. Companies like Hologic, Organon, Cooper Companies, and Boston Scientific are leading the charge.
See a list of transactions in this category from 2021-2024 below:
Private Equity Funds:
Private Equity funds are seeing the light and investing in this tremendous and underserved market. Reputable firms like Carlyle, KKR and L. Catterton are leading the way.
See a list of transactions in this category from 2021-2024 below:
Consumer Packaged Goods (CPG) Conglomerates:
Global CPG giants like Reckitt, Kimberly-Clark, and Essity have long dominated the women’s and sexual health categories. With billions in annual revenue, these firms frequently acquire rather than build, expanding their market share through strategic purchases.
See a list of transactions in this category from 2021-2024 below:
With increasing awareness, technological advancements, and growing consumer demand, we anticipate even more significant transactions in the years ahead. At Amboy Street, we remain committed to tracking and analyzing these deals, ensuring our community stays ahead of the latest trends shaping the future of women’s health.
